Immatics N.V. (IMTX)

NASDAQ: IMTX · Real-Time Price · USD

7.31

-0.23 (-3.05%)

At close: Oct 23, 2026, 4:00 PM EDT

7.40

+0.09 (1.23%)

Pre-market: Oct 26, 2026, 7:20 AM EDT

Revenue

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Moderna, United States Revenue	32.96M	37.25M	62.79M
Bristol-Myers Squibb (BMS), United States Revenue	8.74M	11.02M	78.10M
Genmab, Denmark Revenue	-	-	14.95M
Total Revenue from Collaboration Agreements	41.70M	48.27M	155.84M
Revenue (Total)	41.70M	48.27M	155.84M

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research and Development Expenses	218.42M	183.83M	148.08M